Amicus Therapeutics (FOLD) Receivables - Net (2016 - 2025)
Amicus Therapeutics (FOLD) has disclosed Receivables - Net for 14 consecutive years, with $115.3 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Receivables - Net rose 14.05% year-over-year to $115.3 million, compared with a TTM value of $115.3 million through Dec 2025, up 14.05%, and an annual FY2025 reading of $115.3 million, up 14.05% over the prior year.
- Receivables - Net was $115.3 million for Q4 2025 at Amicus Therapeutics, up from $113.8 million in the prior quarter.
- Across five years, Receivables - Net topped out at $115.3 million in Q4 2025 and bottomed at $44.9 million in Q1 2021.
- Average Receivables - Net over 5 years is $74.9 million, with a median of $70.8 million recorded in 2023.
- The sharpest move saw Receivables - Net rose 1.7% in 2022, then skyrocketed 40.2% in 2023.
- Year by year, Receivables - Net stood at $52.7 million in 2021, then grew by 25.68% to $66.2 million in 2022, then skyrocketed by 32.38% to $87.6 million in 2023, then increased by 15.37% to $101.1 million in 2024, then rose by 14.05% to $115.3 million in 2025.
- Business Quant data shows Receivables - Net for FOLD at $115.3 million in Q4 2025, $113.8 million in Q3 2025, and $105.8 million in Q2 2025.